ACVR2A and neoplasm: VB124 monotherapy exerted suppressive effects on tumor tissues derived from the Hepa1-6 KO cells and 3H3-Pten-KO cells with Acvr2a KO, and its combination with anti-PD-1 antibody significantly enhanced the anti-tumor response (Figures 7E–7L).